Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2016 1
2017 3
2018 4
2019 7
2020 5
2021 5
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Locally Advanced Sarcomatoid Renal Cell Carcinoma"
Page 1
Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions.
Bolek H, Ürün Y. Bolek H, et al. Crit Rev Oncol Hematol. 2023 Dec;192:104144. doi: 10.1016/j.critrevonc.2023.104144. Epub 2023 Sep 23. Crit Rev Oncol Hematol. 2023. PMID: 37748694 Review.
The advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has been transformative for the treatment of advanced renal cell carcinoma (RCC). Their efficacy post-surgical resection remains a contentious point. ...Pembrolizum …
The advent of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has been transformative for the treatment of adva …
Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review.
Bai Y, Li S, Jia Z, Ding Y, Gu C, Yang J. Bai Y, et al. Urol Oncol. 2018 Feb;36(2):79.e1-79.e10. doi: 10.1016/j.urolonc.2017.10.001. Epub 2017 Oct 31. Urol Oncol. 2018. PMID: 29110942 Review.
OBJECTIVES: Many adjuvant therapies have been widely used in an attempt to reduce the local recurrence or distant metastasis of locally advanced renal cell carcinoma (RCC) after surgical resection. ...CONCLUSIONS: The addition of adjuvant …
OBJECTIVES: Many adjuvant therapies have been widely used in an attempt to reduce the local recurrence or distant metastasis of lo …
Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis.
Zalay O, Yan M, Sigurdson S, Malone S, Vera-Badillo FE, Mahmud A. Zalay O, et al. Curr Oncol. 2022 Dec 20;30(1):19-36. doi: 10.3390/curroncol30010002. Curr Oncol. 2022. PMID: 36661651 Free PMC article. Review.
PURPOSE: Upper tract urothelial carcinoma (UTUC) is a rare form of malignancy comprising only 5% of urothelial cancers. The mainstay of treatment is radical nephroureterectomy (RNU) with bladder cuff excision. Neoadjuvant or adjuvant chemotherapy is often used in locall …
PURPOSE: Upper tract urothelial carcinoma (UTUC) is a rare form of malignancy comprising only 5% of urothelial cancers. The mainstay …
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
Yanagisawa T, Kawada T, Quhal F, Bekku K, Laukhtina E, Rajwa P, von Deimling M, Majdoub M, Chlosta M, Pradere B, Mori K, Kimura T, Schmidinger M, Karakiewicz PI, Shariat SF. Yanagisawa T, et al. World J Urol. 2023 Jul;41(7):1763-1774. doi: 10.1007/s00345-023-04412-0. Epub 2023 May 20. World J Urol. 2023. PMID: 37209143 Free PMC article.
PURPOSE: To analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) stratified by sex. ...Adjuvant ICI monotherapy reduced the risk of disease …
PURPOSE: To analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone or in combination therapy for renal cell …
Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
Siva S, Louie AV, Kotecha R, Barber MN, Ali M, Zhang Z, Guckenberger M, Kim MS, Scorsetti M, Tree AC, Slotman BJ, Sahgal A, Lo SS. Siva S, et al. Lancet Oncol. 2024 Jan;25(1):e18-e28. doi: 10.1016/S1470-2045(23)00513-2. Lancet Oncol. 2024. PMID: 38181809
Evidence for using SBRT in the primary renal cell carcinoma setting is growing, including several rigorously conducted prospective clinical trials. ...This systematic review and practice guideline support the practice of SBRT for primary renal cell …
Evidence for using SBRT in the primary renal cell carcinoma setting is growing, including several rigorously conducted …
Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma.
Bekema HJ, MacLennan S, Imamura M, Lam TB, Stewart F, Scott N, MacLennan G, McClinton S, Griffiths TR, Skolarikos A, MacLennan SJ, Sylvester R, Ljungberg B, N'Dow J. Bekema HJ, et al. Eur Urol. 2013 Nov;64(5):799-810. doi: 10.1016/j.eururo.2013.04.033. Epub 2013 Apr 23. Eur Urol. 2013. PMID: 23643550 Review.
CONTEXT: Controversy remains over whether adrenalectomy and lymph node dissection (LND) should be performed concomitantly with radical nephrectomy (RN) for locally advanced renal cell carcinoma (RCC) cT3-T4N0M0. OBJECTIVE: To systematically revi …
CONTEXT: Controversy remains over whether adrenalectomy and lymph node dissection (LND) should be performed concomitantly with radical nephr …
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.
Iacovelli R, Nolè F, Verri E, Renne G, Paglino C, Santoni M, Cossu Rocca M, Giglione P, Aurilio G, Cullurà D, Cascinu S, Porta C. Iacovelli R, et al. Target Oncol. 2016 Apr;11(2):143-8. doi: 10.1007/s11523-015-0392-7. Target Oncol. 2016. PMID: 26429561 Review.
OBJECTIVE: To investigate the prognostic role of PD-L1 expression in patients affected by renal cell carcinoma (RCC). METHODS: MEDLINE/PubMed, the Cochrane Library, and ASCO University were searched for studies investigating the prognostic role of PD-L1 expre …
OBJECTIVE: To investigate the prognostic role of PD-L1 expression in patients affected by renal cell carcinoma (RCC). M …
Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Zhang F, Wang Y, Wang ZQ, Sun P, Wang DS, Jiang YX, Zhang DS, Wang FH, Xu RH, Li YH. Zhang F, et al. Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12490. Dis Esophagus. 2017. PMID: 27868295 Review.
Cisplatin and nedaplatin show significant antitumor activity and have been widely used for esophageal squamous cell carcinoma (ESCC). However, it is still unclear whether the efficacy and safety of nedaplatin-based regimens are comparable to those of cisplatin-based …
Cisplatin and nedaplatin show significant antitumor activity and have been widely used for esophageal squamous cell carcinoma …
The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Yiu W, Chen J, Zhao B, Zhang W, Chen L, Liu H. Yiu W, et al. Comput Math Methods Med. 2022 Mar 29;2022:7341294. doi: 10.1155/2022/7341294. eCollection 2022. Comput Math Methods Med. 2022. PMID: 35392587 Free PMC article. Retracted.
BACKGROUND: The aim of this systematic evaluation and meta-analysis was to analyze the efficacy and adverse effects of adjuvant targeted therapy regimens in advanced or metastatic renal cell carcinoma (RCC). METHODS: Studies eligible for the efficacy o …
BACKGROUND: The aim of this systematic evaluation and meta-analysis was to analyze the efficacy and adverse effects of adjuvant targeted the …
Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis.
Riaz IB, Siddiqi R, Islam M, He H, Riaz A, Asghar N, Naqvi SAA, Warner JL, Murad MH, Kohli M. Riaz IB, et al. JCO Clin Cancer Inform. 2021 May;5:588-599. doi: 10.1200/CCI.21.00035. JCO Clin Cancer Inform. 2021. PMID: 34043431 Free article.
PURPOSE: Multiple large clinical trials have investigated adjuvant tyrosine kinase inhibitors (TKIs) to reduce the risk of cancer recurrence and progression to metastasis in high-risk renal cell carcinoma. We sought to maintain living and interactive evidence …
PURPOSE: Multiple large clinical trials have investigated adjuvant tyrosine kinase inhibitors (TKIs) to reduce the risk of cancer recurrence …
29 results